Last reviewed · How we verify
Actilitio®
Actilitio is a monoclonal antibody that targets the PD-1 receptor.
Actilitio is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma, Urothelial carcinoma.
At a glance
| Generic name | Actilitio® |
|---|---|
| Also known as | lithium carbonate |
| Sponsor | Centro de Atencion e Investigacion Medica |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
By binding to PD-1, Actilitio prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
- Urothelial carcinoma
- Renal cell carcinoma
- Gastric cancer
- Esophageal cancer
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
- Cervical cancer
- Hepatocellular carcinoma
- Mucosal melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
- Diarrhea
- Colitis
- Pneumonia
- Nephritis
- Arthralgia
- Myalgia
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |